GO:0060947 cardiac vascular smooth muscle cell differentiation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060947 describes the process by which a relatively unspecialized cell acquires the specialized features of a cardiac vascular smooth muscle cell, a contractile cell covering the heart vasculature that lacks transverse striations.
• Cardiac vascular smooth muscle cells (cVSMCs) arise from multiple embryonic origins and can be modeled in vitro from human pluripotent stem cells (hPSCs) and induced pluripotent stem cells (iPSCs).
• Key transcriptional regulators include TEAD1, VGLL4, TET2, and SRF-associated cofactors, which drive contractile gene expression during differentiation.
• Phenotypic switching of vascular smooth muscle cells (VSMCs) from a contractile to a synthetic state underlies atherosclerosis and restenosis, making differentiation state a central disease variable.
• Mechanical cues (stretch via PIEZO1) and metabolic state (glycolysis) integrate with transcriptional programs to control smooth muscle cell plasticity.
• Premature cell senescence promotes VSMC phenotypic modulation and resistance to re-differentiation, linking aging biology to vascular disease.
Description
Cardiac vascular smooth muscle cell differentiation (GO:0060947) is the biological process in which a relatively unspecialized cell acquires the specialized features of a cardiac vascular smooth muscle cell, a cell type that covers the heart vasculature and lacks transverse striations in its constituent fibers. This process is fundamental to the development and maintenance of the coronary vasculature, where contractile smooth muscle cells regulate blood flow, vessel tone, and structural integrity. Understanding how cVSMCs differentiate from progenitors is essential for vascular biology, regenerative medicine, and disease modeling. In the adult organism, vascular smooth muscle cells (VSMCs) retain remarkable plasticity. They can switch between a contractile, differentiated phenotype and a synthetic, proliferative phenotype in response to injury or disease. This phenotypic switching is a hallmark of atherosclerosis, where VSMCs migrate, proliferate, and contribute to plaque formation. The differentiation state of these cells is therefore not only a developmental question but also a central determinant of vascular pathology. Recent advances in stem cell biology have enabled the derivation of cVSMCs from human pluripotent stem cells (hPSCs) and induced pluripotent stem cells (iPSCs), providing tractable models to study GO:0060947. These models have revealed that transcriptional networks involving TEAD1, VGLL4, and TET2, as well as mechanical and metabolic cues, orchestrate the differentiation process. This article synthesizes the current understanding of cVSMC differentiation, its regulatory mechanisms, its role in disease, and the experimental methods used to study it.
cardiac vascular smooth muscle cell differentiation At A Glance
| GO ID | GO:0060947 |
|---|---|
| GO term | cardiac vascular smooth muscle cell differentiation |
| Ontology | biological_process |
| Synonym | heart vascular smooth muscle cell differentiation |
| Major function | Acquisition of specialized features of cardiac vascular smooth muscle cells that cover the heart vasculature and lack transverse striations |
| Cell type | Cardiac vascular smooth muscle cell |
| Tissue context | Heart vasculature |
| Related processes | Vascular smooth muscle cell differentiation, phenotypic switching, contractile gene expression |
What Is GO:0060947?
GO:0060947, cardiac vascular smooth muscle cell differentiation, is defined as the process in which a relatively unspecialized cell acquires specialized features of a cardiac vascular smooth muscle cell. A cardiac vascular smooth muscle cell covers the heart vasculature and lacks transverse striations in its constituent fibers. This term is a biological process and is synonymous with heart vascular smooth muscle cell differentiation.
Why Is cardiac vascular smooth muscle cell differentiation Important in Cell Biology?
Cardiac vascular smooth muscle cell differentiation is critical for the development and homeostasis of the coronary vasculature, and its dysregulation contributes to major human diseases including atherosclerosis, restenosis, and ischemic heart disease. Because VSMCs retain phenotypic plasticity, the differentiation state of these cells determines whether they maintain contractile function or adopt a synthetic, disease-promoting phenotype. Understanding GO:0060947 therefore informs both developmental biology and therapeutic strategies aimed at promoting vascular repair or preventing pathological remodeling.
• Defines the contractile identity of smooth muscle cells that regulate coronary blood flow and vessel tone.
• Phenotypic switching from contractile to synthetic VSMCs is a central mechanism in atherosclerosis.
• Loss of differentiation and resistance to re-differentiation are promoted by premature cell senescence.
• Differentiation protocols from hPSCs/iPSCs enable disease modeling and drug screening.
• Mechanical stretch via PIEZO1 integrates with glycolytic metabolism to regulate smooth muscle cell plasticity.
• Hydrogel-based approaches can drive differentiation of cardiac vascular smooth muscle progenitor cells for ischemic treatment.
• Transcriptional regulators such as VGLL4-TEAD1 and TET2 control the differentiation program.
• Understanding cVSMC differentiation supports tissue engineering of vascular grafts and regenerative therapies.
What Happens During cardiac vascular smooth muscle cell differentiation?
Commitment of progenitors to the smooth muscle lineage
In simple terms: Unspecialized cells decide to become heart blood vessel muscle cells.
The first step in GO:0060947 is the commitment of progenitor cells to the cardiac vascular smooth muscle lineage. These progenitors can originate from multiple embryonic sources, and in vitro they can be derived from human pluripotent stem cells (hPSCs) or induced pluripotent stem cells (iPSCs). Differentiation protocols typically involve sequential activation of signaling pathways that mimic embryonic development, leading to the emergence of smooth muscle progenitor cells that express early markers such as PDGFRB and TAGLN. The commitment step is characterized by the loss of pluripotency markers and the onset of smooth muscle-specific gene expression.
Transcriptional activation of the contractile program
In simple terms: Master switches turn on the genes that make the cell contractile.
Once committed, progenitors activate a transcriptional program that drives expression of contractile proteins. The VGLL4-TEAD1 complex promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2, which likely influences DNA demethylation and chromatin accessibility at contractile gene loci. This transcriptional network induces genes such as ACTA2, MYH11, CNN1, and TAGLN, which encode the structural and regulatory components of the contractile apparatus. The coordinated expression of these genes establishes the specialized features of cardiac vascular smooth muscle cells.
Acquisition of specialized morphological and functional features
In simple terms: The cell changes shape and function to become a mature heart vessel muscle cell.
As differentiation proceeds, cells acquire the morphological and functional characteristics of mature cardiac vascular smooth muscle cells. These cells cover the heart vasculature and lack transverse striations in their constituent fibers, distinguishing them from skeletal and cardiac muscle cells. They become elongated, develop a robust contractile apparatus, and express ion channels and signaling molecules that enable responses to vasoactive stimuli. This maturation step is essential for the cell to perform its role in regulating vascular tone and blood flow.
Integration of mechanical and metabolic cues
In simple terms: Physical forces and energy metabolism help shape the final cell identity.
Mechanical and metabolic cues are integrated into the differentiation process. PIEZO1, a mechanosensitive ion channel, regulates smooth muscle cell plasticity by integrating mechanical stretch with glycolytic metabolism. This suggests that hemodynamic forces in the heart vasculature actively participate in maintaining or modulating the differentiated state. Metabolic pathways, particularly glycolysis, are therefore not merely supportive but instructive for smooth muscle cell phenotype. This integration ensures that cVSMCs adapt appropriately to the mechanical environment of the beating heart.
Maintenance and plasticity of the differentiated state
In simple terms: Even after maturing, these cells can change back, which matters in disease.
The differentiated state of cardiac vascular smooth muscle cells is not terminal; these cells retain the capacity for phenotypic switching. In response to injury or pathological stimuli, they can downregulate contractile markers and adopt a synthetic, proliferative phenotype. Premature cell senescence promotes this phenotypic modulation and confers resistance to re-differentiation, linking aging to vascular disease. Understanding the balance between maintenance and plasticity is crucial for developing therapies that preserve or restore the contractile phenotype.
Key Genes Involved in GO:0060947 cardiac vascular smooth muscle cell differentiation
The following genes and proteins are experimentally implicated in cardiac vascular smooth muscle cell differentiation and its regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TEAD1 | Transcription factor that partners with VGLL4 to promote VSMC differentiation | Central to transcriptional control of contractile gene expression |
| VGLL4 | Coactivator that forms a complex with TEAD1 to drive differentiation via TET2 | Key regulator of hPSC-derived VSMC differentiation |
| TET2 | DNA demethylase involved in epigenetic regulation of differentiation | Mediates VGLL4-TEAD1 effects on differentiation |
| ACTA2 | Smooth muscle alpha-actin, a contractile protein | Marker of differentiated VSMCs |
| MYH11 | Smooth muscle myosin heavy chain, a contractile protein | Marker of contractile VSMC phenotype |
| CNN1 | Calponin 1, a contractile regulatory protein | Marker of differentiated VSMCs |
| TAGLN | Transgelin, an actin-binding protein | Early marker of smooth muscle lineage |
| PDGFRB | Platelet-derived growth factor receptor beta | Expressed in smooth muscle progenitors |
| PIEZO1 | Mechanosensitive ion channel | Integrates mechanical stretch with glycolytic metabolism to regulate plasticity |
| SRF | Serum response factor, a transcription factor | Cooperates with cofactors to activate contractile genes |
| MYOCD | Myocardin, a transcriptional coactivator | Master regulator of smooth muscle contractile program |
| KLF4 | Kruppel-like factor 4 | Promotes synthetic VSMC phenotype and phenotypic switching |
| KLF5 | Kruppel-like factor 5 | Regulates VSMC proliferation and differentiation |
| NOTCH | Notch signaling pathway components | Influence VSMC differentiation and fate |
| TGFB1 | Transforming growth factor beta 1 | Promotes contractile VSMC differentiation |
| PDGF-BB | Platelet-derived growth factor BB | Promotes synthetic VSMC phenotype |
| IL-6 | Interleukin-6 | Inflammatory cytokine linked to VSMC phenotypic modulation |
How Is cardiac vascular smooth muscle cell differentiation Regulated?
The differentiation of cardiac vascular smooth muscle cells is regulated at multiple levels. Transcriptional control involves the VGLL4-TEAD1 complex, which promotes differentiation from human pluripotent stem cells via TET2-dependent epigenetic remodeling. SRF and MYOCD cooperate to activate contractile gene expression. Mechanical regulation is mediated by PIEZO1, which integrates mechanical stretch with glycolytic metabolism to control smooth muscle cell plasticity. Metabolic cues, including glycolysis, are therefore instructive for phenotype. In addition, premature cell senescence promotes phenotypic modulation and resistance to re-differentiation, indicating that aging-related pathways regulate the stability of the differentiated state. Inflammatory and growth factor signaling, such as PDGF-BB and TGFB1, also modulate the balance between contractile and synthetic phenotypes.
cardiac vascular smooth muscle cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACTA2 | Atherosclerosis, VSMC phenotypic switching | Knockout or point mutation in hPSC-derived VSMCs |
| MYH11 | Atherosclerosis, contractile dysfunction | Knock-in of reporter for contractile state |
| KLF4 | Atherosclerosis, synthetic VSMC phenotype | Overexpression or knockout in VSMC cultures |
| PIEZO1 | Vascular plasticity, mechanotransduction | Point mutation or knockout in mechanostimulation models |
| TET2 | Epigenetic regulation of differentiation | Knockout in hPSC-derived VSMCs |
Atherosclerosis and phenotypic switching
Atherosclerosis is characterized by the accumulation of lipids and fibrous elements in the arterial wall, in which vascular smooth muscle cells play a central role. During atherogenesis, VSMCs undergo phenotypic switching from a contractile to a synthetic state, migrating from the media to the intima and contributing to plaque formation. This switch involves downregulation of contractile markers such as ACTA2 and MYH11 and upregulation of synthetic markers. The differentiation state of VSMCs is therefore a key determinant of plaque stability and disease progression.
Premature senescence and resistance to re-differentiation
Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation. Senescent VSMCs exhibit reduced expression of contractile proteins and impaired ability to return to a differentiated state, contributing to vascular aging and disease. This link between senescence and differentiation failure highlights the importance of understanding GO:0060947 in the context of age-related vascular pathologies.
Ischemic heart disease and regenerative approaches
Ischemic heart disease involves reduced blood flow to the myocardium, often due to coronary artery disease. Differentiation of cardiac vascular smooth muscle progenitor cells is a potential therapeutic strategy for ischemic treatment. Keratose hydrogel has been shown to drive differentiation of cardiac vascular smooth muscle progenitor cells, suggesting that biomaterial-based approaches can promote vascular repair. Understanding the differentiation process is therefore directly relevant to regenerative medicine for ischemic heart disease.
From cardiac vascular smooth muscle cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene impair cVSMC differentiation? | CRISPR knockout in hPSC/iPSC-derived VSMCs |
| Does a specific point mutation alter contractile function? | Point-mutation knock-in in VSMC lines |
| Can a reporter track contractile gene expression? | Knock-in of fluorescent reporter at ACTA2 or MYH11 locus |
| Does overexpression of a transcription factor drive differentiation? | Overexpression of VGLL4 or TEAD1 in progenitors |
| How does mechanical stretch affect differentiation? | PIEZO1 knockout or point mutation under stretch |
| Does a hydrogel promote differentiation? | Keratose hydrogel culture of cardiac vascular smooth muscle progenitor cells |
How to Study the cardiac vascular smooth muscle cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify contractile and synthetic markers during differentiation |
| ATAC-seq | Chromatin accessibility | Map regulatory elements and TET2-dependent remodeling |
| Immunofluorescence | Protein localization and morphology | Confirm expression of ACTA2, MYH11, CNN1 |
| Collagen gel contraction | Contractile function | Assess functional maturation of VSMCs |
| Mechanical stretch | Response to mechanical forces | Study PIEZO1-mediated mechanotransduction |
| Glycolytic flux assay | Metabolic activity | Link glycolysis to differentiation state |
| Flow cytometry | Surface marker expression | Isolate progenitor and differentiated populations |
| Western blot | Protein expression levels | Quantify contractile protein levels |
Stem cell differentiation and lineage tracing
Human pluripotent stem cells (hPSCs) and induced pluripotent stem cells (iPSCs) can be differentiated into vascular smooth muscle cells using defined protocols. These methods typically involve sequential treatment with growth factors and small molecules to mimic embryonic development. Lineage tracing using reporter genes or surface markers allows isolation of differentiated cells for downstream analysis.
Transcriptomic and epigenomic profiling
RNA sequencing (RNA-seq) is widely used to profile gene expression changes during cVSMC differentiation, revealing contractile and synthetic gene signatures. Epigenomic approaches such as ATAC-seq and DNA methylation profiling can identify regulatory elements and the role of TET2 in demethylation. These methods provide a global view of the transcriptional and epigenetic networks controlling differentiation.
Mechanical and metabolic assays
Mechanical stretch devices and microfluidic systems can apply controlled forces to cultured VSMCs to study mechanotransduction. Metabolic assays, including glycolytic flux measurements, reveal how energy metabolism integrates with differentiation. PIEZO1 function can be probed using pharmacological agonists or genetic manipulation.
Imaging and contractility measurements
Immunofluorescence and live-cell imaging can visualize contractile protein organization and cell morphology. Contractility can be assessed using collagen gel contraction assays or traction force microscopy. These methods confirm the functional maturation of differentiated cVSMCs.
How CRISPR Can Be Used to Study GO:0060947 cardiac vascular smooth muscle cell differentiation
Knockout
CRISPR knockout of candidate genes in hPSC or iPSC-derived vascular smooth muscle cells can determine whether a gene is required for differentiation. For example, knocking out TET2 would test its role in VGLL4-TEAD1-mediated differentiation. Knockout of contractile genes such as ACTA2 can reveal their contribution to the differentiated phenotype.
Point Mutation
Point mutations can be introduced to model specific amino acid changes that may affect protein function without completely abolishing expression. This is useful for studying mechanosensitive channels like PIEZO1, where point mutations can alter ion conductance or mechanosensitivity. Point mutations in contractile proteins can model inherited vascular disorders.
Knock-in
Knock-in of reporter genes, such as fluorescent proteins, at endogenous loci (e.g., ACTA2, MYH11) allows real-time monitoring of differentiation and isolation of pure populations. Knock-in of epitope tags facilitates protein interaction and localization studies. This approach is valuable for tracking the transition from progenitor to differentiated cell.
Overexpression
Overexpression of transcription factors or coactivators, such as VGLL4 or TEAD1, can drive or enhance differentiation from progenitors. Overexpression of KLF4 or KLF5 can promote the synthetic phenotype, providing a model for phenotypic switching. These models help dissect the sufficiency of individual factors in the differentiation process.
How EDITGENE Supports cardiac vascular smooth muscle cell differentiation Research
Researchers studying cardiac vascular smooth muscle cell differentiation-related genes often need to determine whether a candidate gene is causally involved in the differentiation process, and to dissect its mechanism of action. This requires precise genetic manipulation in relevant cell models, such as hPSC-derived VSMCs or primary smooth muscle cells.
Contact EDITGENE today to design your custom CRISPR model for cardiac vascular smooth muscle cell differentiation research.
Frequently Asked Questions About cardiac vascular smooth muscle cell differentiation
What is GO:0060947?
GO:0060947 is the Gene Ontology term for cardiac vascular smooth muscle cell differentiation, the process in which a relatively unspecialized cell acquires the specialized features of a cardiac vascular smooth muscle cell, which covers the heart vasculature and lacks transverse striations.
What genes are involved in cardiac vascular smooth muscle cell differentiation?
Key genes include TEAD1, VGLL4, TET2, ACTA2, MYH11, CNN1, TAGLN, and PIEZO1, among others.
How are cardiac vascular smooth muscle cells derived from stem cells?
They can be derived from human pluripotent stem cells or induced pluripotent stem cells using defined differentiation protocols that mimic embryonic development.
What is the role of VGLL4-TEAD1 in VSMC differentiation?
The VGLL4-TEAD1 complex promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2, likely through epigenetic remodeling.
How does PIEZO1 regulate smooth muscle cell plasticity?
PIEZO1 integrates mechanical stretch with glycolytic metabolism to regulate smooth muscle cell plasticity and differentiation state.
What is phenotypic switching in vascular smooth muscle cells?
Phenotypic switching is the process by which VSMCs change from a contractile, differentiated state to a synthetic, proliferative state, which occurs in atherosclerosis and restenosis.
How does cell senescence affect VSMC differentiation?
Premature cell senescence promotes VSMC phenotypic modulation and resistance to re-differentiation, linking aging to vascular disease.
What experimental models are used to study cardiac vascular smooth muscle cell differentiation?
Models include hPSC/iPSC-derived VSMCs, primary VSMC cultures, and genetically modified cell lines using CRISPR knockout, knock-in, or overexpression.
Can hydrogels promote cardiac vascular smooth muscle differentiation?
Yes, keratose hydrogel has been shown to drive differentiation of cardiac vascular smooth muscle progenitor cells, with implications for ischemic treatment.
Why is cardiac vascular smooth muscle cell differentiation important for disease?
Dysregulation of this process contributes to atherosclerosis, restenosis, and ischemic heart disease, making it a target for therapeutic intervention.
Conclusion
Cardiac vascular smooth muscle cell differentiation (GO:0060947) is a fundamental biological process that governs the formation and maintenance of the coronary vasculature. It is controlled by a complex interplay of transcriptional regulators, epigenetic modifiers, mechanical cues, and metabolic signals. Disruption of this process contributes to major vascular diseases, including atherosclerosis and ischemic heart disease. Continued research using stem cell models and CRISPR-based genetic tools will further elucidate the mechanisms of cVSMC differentiation and inform new therapeutic strategies.
References
- 1. Bennett MR et al.. 2016. Vascular Smooth Muscle Cells in Atherosclerosis.. Circ Res 118(4):692-702 PMID: 26892967
- 2. Chen R et al.. 2023. Phenotypic Switching of Vascular Smooth Muscle Cells in Atherosclerosis.. J Am Heart Assoc 12(20):e031121 PMID: 37815057
- 3. Kaistha A et al.. 2025. Premature cell senescence promotes vascular smooth muscle cell phenotypic modulation and resistance to re-differentiation.. Cardiovasc Res 121(9):1448-1463 PMID: 40493738
- 4. Wang Z et al.. 2023. VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2.. J Mol Cell Cardiol 176:21-32 PMID: 36657637
- 5. Ledford BT et al.. 2023. Keratose Hydrogel Drives Differentiation of Cardiac Vascular Smooth Muscle Progenitor Cells: Implications in Ischemic Treatment.. Stem Cell Rev Rep 19(7):2341-2360 PMID: 37392292
- 6. Steinbach SK et al.. 2016. Vascular smooth muscle cell differentiation from human stem/progenitor cells.. Methods 101:85-92 PMID: 26678794
- 7. Cao Y et al.. 2026. PIEZO1 regulates smooth muscle cell plasticity by integrating mechanical stretch with glycolytic metabolism.. Cardiovasc Res 122(6):748-763 PMID: 41846580
- 8. Maguire EM et al.. 2017. Differentiation and Application of Induced Pluripotent Stem Cell-Derived Vascular Smooth Muscle Cells.. Arterioscler Thromb Vasc Biol 37(11):2026-2037 PMID: 28860223
